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ABSTRACT

Autism Spectrum Disorder is a grouping of disorders that range from the
diagnosis of Asperger Syndrome to Autistic Disorder (formally known as autism).
Attention Deficit Disorders and Pervasive Developmental Disorder-Not Otherwise
Specified are also a part of this spectrum of disorders. Autism Spectrum Disorder affects
one out of every 110 children and has a male to female ratio of 4:1. This has led to the
need to identify genes that may be causative for this disorder.
Several genome-wide scans have been conducted and have identified locations in
the human genome that may contain causative genes for Autism Spectrum Disorder. One
such area was found to be located at chromosome 7q and included the MET gene.
Campbell et al. (2006) identified the rs1858830 C variant in the MET gene and a study
found it to be associated with ASD. Screening of the rs1858830 C variant in the MET
gene was conducted in a unique population comprised of individuals diagnosed with
Autistic Disorder and controls. Results indicated that this variant was associated with
Autistic Disorder.
The high male to female ratio of individuals affected with Autism Spectrum
Disorder raises the possibility that genes on the X chromosome may be involved in these
disorders. Alterations in NLGN4X, which is involved in neuronal synapse formation and
located at Xq22.2, have previously been identified that are associated with Autism
Spectrum Disorder. We screened a cohort of individuals diagnosed with Autistic
Disorder for any alterations in NLGN4X. We identified two alterations in NLGN4X
within this cohort. Further studies were conducted to observe cell morphology after
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transfection with the altered NLGN4X proteins in PC12 cells, a rat pheochromocytoma
cell line. Fluorescence microscopy determined that neuronal cells expressing the two
altered forms of NLGN4X had altered cell morphology. Cellular localization studies also
identified a difference between the location of the altered NLGN4X proteins within the
cell and the location of wild type NLGN4X.
To further identify causative genes for Autism Spectrum Disorder, the
translocation breakpoint region at chromosome 2q21 of a patient with a chromosomal
translocation t(2;16) and autistic like characteristics was partially mapped. The
breakpoint at chromosome 2q was narrowed to a region of only 80kb in size and one
candidate Autism Spectrum Disorder gene within this region was identified.
The understanding and identification of Autism Spectrum Disorder causative
genes is very important given the large number of individuals that are affected. The wide
range of phenotypes associated with this disorder implies the involvement of many genes
that lead to different phenotypes. The studies within this dissertation determined that
Autistic Disorder is associated with an alteration in the MET gene, identified two
alterations, one being de novo, in NLGN4X that are associated with Autistic Disorder, and
provided cellular studies of the NLGN4X alterations in a neuronal cell line. Additionally,
this research revealed candidate genes located at chromosome 2q21 that may be
associated with Autism Spectrum Disorder.
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Background

Autism was first identified and formally described in 1943 by Dr. L. Kanner from
a study of eleven children that he diagnosed with the syndrome (Kanner, 1943). A year
later Dr. Kanner published an additional paper and identified the syndrome as infantile
autism, indicating that the syndrome begins even in early infancy (Kanner, 1944). The
terms infantile autism, childhood autism, and autistic child were utilized until fairly
recently to identify an individual with the disorder (Ornitz, 1973). Hans Asperger, in
1944, was conducting research in child psychiatric disorders and noted four individuals
that displayed focused and unusual behaviors (Asperger, 1944). He predicted that these
individuals would later in life be very successful in their area of focus. Asperger
diagnosed these individuals as having autistic psychopathy, which would later be
identified as Asperger syndrome (Asperger, 1944). Asperger syndrome is currently
known as high functioning autism (American Psychiatric Association, 1994). The
identification and description of these syndromes led to the formation of the current three
subgroups for autism: Autistic Disorder, Asperger syndrome, and Pervasive
Developmental Disorder Not Otherwise Specified (PDD-NOS) (American Psychiatric
Association, 1994). All three of these subgroups fall in the Autism Spectrum Disorder
classification.
Autism Spectrum Disorder has a range of phenotypes that includes mental
retardation, developmental delays, impairments in communication and social skills, and
abnormal behaviors and interests (Folstein and Mankoski, 2000; Lamb et al., 2005;

Muhle, Trentacoste, and Rapin, 2004; Rutter, 2005; Veenstra-VanderWeele and Cook,
2004). The diagnosis of one of the three subgroups in Autism Spectrum Disorder is
determined based upon social interaction, language utilized during social interaction, and
restricted patterns of interest. The diagnosis of Autistic Disorder is given to an individual
that has abnormalities in all three of these categories occurring before the age of three.
The diagnosis of Asperger syndrome or PDD-NOS may be given if criteria are not met
for a diagnosis of Autistic Disorder (Centers for Disease Control and Prevention, 2009).
Autism Spectrum Disorder has a prevalence of one in 110 children, while Autistic
Disorder has a prevalence of one in 500 children (Centers for Disease Control and
Prevention, 2009; Fombonne, 1999; Herba, et al., 2008; Yeargin-Allsop et al., 2003).
The male to female ratio of the individuals diagnosed with Autistic Disorder is 4:1
(Fombonne, 1999; Ylisaukko-oja et al., 2005). The high prevalence of Autism Spectrum
Disorder and the early age of onset have driven the desire to identify causative genes for
this spectrum of disorders.
Genome-wide linkage scans were used to identify locations in the human genome
that may contain causative genes for Autism Spectrum Disorder. Genome-wide
association studies have identified chromosomal regions 2q, 4, 7q, 15q, 16p, 17q, 19, and
22q as putative locations for Autism Spectrum Disorder genes (Ashley-Koch et al., 1999;
Barrett et al., 1999; Folstein and Rosen-Sheidley, 2001; Gutknecht et al., 2001; Herba et
al., 2008; International Molecular Genetic Study of Autism Consortium, 1998; Philippe et
al., 1999; Risch et al., 1999; Schellenberg et al., 2006; Trikalinos et al., 2006; Vincent et
al., 2000).
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Previous studies identified alterations in the MET gene, located at chromosome 7q31, that
were associated with Autism Spectrum Disorder (Campbell et al., 2006). The MET gene
is unique because it is involved not only in the metastasis of a variety of cancers,
peripheral organ development and repair, and immune function and gastrointestinal
repair, but it may contribute to the development of the cerebral cortex and cerebrum
(Blume-Jensen and Hunter, 2001; Campbell et al., 2007; Gherdi et al., 2003; Ierci, Forni,
and Ponzetto, 2002; Park et al., 1987; Powell, Mars, and Levitt, 2001; Powell et al., 2003;
Tahara et al., 2003). Since MET is involved in brain development, the rs1858830 C
variant may contribute to the cognitive dysfunction identified in ASD patients. Previous
studies in mice demonstrated that MET contributes to brain development (Campbell et al.,
2007; Powell, Mars, and Levitt, 2001; Powell et al., 2003; Levitt, 2005; Ierci et al., 2002;
Gutierrez et al., 2004; Tyndall et al., 2007; Tyndall et al., 2006). This is a result of MET
involvement in neuronal migration, dendritic arborization, and synapse formation in the
developing brain (Campbell et al., 2007). Studies have observed reduced signaling of
MET in the brains of mice resulting in a reduction of migration and differentiation of
neocortical and hippocampal interneurons. The mice with these abnormalities had
seizures, increased anxiety, and abnormal social behavior (Campbell et al., 2007; Powell,
Mars, and Levitt, 2001; Levitt, 2005; Powell et al., 2003).
The reduction of MET expression also leads to a decrease in granule cells and a
smaller cerebellum (Ierci, Forni, and Ponzetto, 2002). Granule cells are very small, but
numerous, neurons that are found in the cerebellum, hippocampus, and olfactory bulb,
that are responsible for receiving sensory information (Gilbert, 2003). The granule cells
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of the cerebellum account for half the neurons in the entire central nervous system
(Gilbert, 2003). A reduction in the size of the cerebellum is a classic feature in the brains
of individuals affected with Autism Spectrum Disorder (Bauman and Kemper, 2005).
The cerebellum is a part of the brain that is responsible for coordinating movement, long
term memory, and olfaction (Gilbert, 2003). Based upon known functions of the
hippocampus and cerebellum, and autistic phenotypes resulting from abnormalities of the
cerebellum and hippocampus that have been previously described, it is very likely that
alterations of the MET gene may lead to Autism Spectrum Disorder.
The role the MET gene plays in gastrointestinal repair is relevant because of the
presence of gastrointestinal problems in individuals with Autism Spectrum Disorder
(Goodwin, Cowen, and Goodwin, 1971; Horvath et al., 1999; Jyonouchi et al., 2005;
Wakefield et al., 2000; Wakefield et al., 1998). However, the alterations in MET would
not account for all gastrointestinal problems. Individuals with Autism Spectrum Disorder
have a difficult time functioning in society and difficulty communicating their needs or
problems, and this could result in gastrointestinal problems being untreated and reducing
the individual’s ability to interact with society. Further, the identification of alterations in
this gene may indicate the need to test an individual with Autism Spectrum Disorder for
gastrointestinal problems.
The 4:1 male to female ratio observed in Autism Spectrum Disorder implies the
possibility that there are genes residing on the X chromosome that cause Autism
Spectrum Disorder (Centers for Disease Control and Prevention, 2009; Ylisaukko-oja et
al., 2005). Specifically, alterations of NLGN4X at chromosome Xp22.3 have been found
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to be associated with Autism Spectrum Disorder (Jamain et al., 2003). NLGN4X is
involved in the production of cell-adhesion molecules that are important for the formation
and organization of functional synapses (Talebizadeh et al., 2004). The synapse is the
specialized junction between the neurite (or axon) of a neuron and its target. The synapse
is established as neurites extend from presynaptic neurons and grow until they reach their
specific postsynaptic partner(s) (Sanes and Yamagata, 1999). The neurite target or
postsynaptic partner may either be another neurite or muscle (Gilbert, 2003). At the
synapse, the neurotransmitter or chemical message is released and functions to depolarize
or hyperpolarize the membrane of the target cell (Gilbert, 2003). The stability of
synapses is achieved through trans-synaptic adhesion complexes that link the presynaptic
and postsynaptic domains (Fannon and Colman, 1996; Yamagata et al., 2003).
NLGN4X is a member of the neuroligin family of proteins that forms the
neuroligin-neurexin complex that links the presynaptic and postsynaptic domains of
neuronal synapses (Benson et al., 2000; Scheiffele, 2003; Waites et al., 2005).
Neuroligins are the postsynaptic proteins, while neurexins are the presynaptic proteins of
the trans-synaptic adhesion complex formed by neuroligin and neurexin. Previous
studies have indicated that neurexin functions as a neuroligin receptor during synapse
formation (Dean et al., 2003). Neuroligins recruit neurexins, and this action triggers the
assembly of presynaptic active zones. This occurs when the extracellular domain of
neuroligin on the postsynaptic neuron signals the induction of presynaptic specialization
on the presynaptic neuron (Scheiffele et al., 2000). All of these activities illustrate how
neuroligins are essential in the formation and stabilization of synapses.
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Figure B1.1 Schematic representation of NLGN4X functioning at the postsynaptic
neuron. NLGN4X along with PSD (postsynaptic density protein) and SHANK3
form a complex that helps to stabilize the synapse.

The studies in this dissertation investigated causative genes for Autism Spectrum
Disorder. The rs1858830 C variant in the MET gene was previously identified and
associated with Autism Spectrum Disorder by Campbell et al. (2006). We attempted to
determine the importance of this variant and its association with Autistic Disorder. We
also attempted to identify alterations in NLGN4X and study the in vivo effects of
identified NLGN4X alterations in a neuronal cell line. Finally, the chromosomal region
located at 2q21 has been implicated as a location for causative Autism Spectrum Disorder
genes (Ashley-Koch et al., 1999; Barrett et al., 1999; Folstein and Rosen-Sheidley, 2001;
Gutknecht et al., 2001; Herba et al., 2008; International Molecular Genetic Study of
Autism Consortium, 1998; Philippe et al., 1999; Risch et al., 1999; Schellenberg et al.,
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2006; Trikalinos et al., 2006; Vincent et al., 2000). We attempted to locate the
translocation breakpoint at chromosome 2q21 in a patient with a t(2;16) translocation and
identify causative genes for Autism Spectrum Disorder located in this region.
The first study involved screening a cohort containing individuals diagnosed with
Autistic Disorder and a cohort of controls to identify the significance of the rs1858830 C
variant of the MET gene and Autistic Disorder. This cohort of individuals diagnosed
with Autistic Disorder is quite unique because it represents a very small percentage of
individuals that fall within Autism Spectrum Disorder. Results obtained from screening
the cohorts for the rs1858830 C variant indicated an association with the MET rs1858830
C variant and Autistic Disorder.
The second study involved screening a cohort containing individuals diagnosed
with Autistic Disorder and a cohort of controls to identify alterations in NLGN4X. Two
alterations were identified in NLGN4X, one of which is a de novo alteration, within the
Autistic Disorder cohort. Further studies were conducted to observe the cellular
localization and cell morphology of these alterations in a neuronal cell line. Fluorescence
microscopy determined that neuronal cells expressing the two alterations identified in
NLGN4X did have altered cell morphology. The cells transfected with the altered
NLGN4X protein had reduced neurite lengths and a reduction in the number of neurites
per transfected cell as compared to cells transfected with wild type NLGN4X protein.
Cellular localization studies also identified a difference between the location of the
altered NLGN4X protein within the cell and the location of wild type NLGN4X.
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The final study attempted to identify causative genes for Autism Spectrum
Disorder located in the 2q21 chromosomal region. Previous genome-wide linkage scans
identified 2q as possibly containing genes associated with Autism Spectrum Disorder
(Ashley-Koch et al., 1999; Barrett et al., 1999; Folstein and Rosen-Sheidley, 2001;
Gutknecht et al., 2001; Herba et al., 2008; International Molecular Genetic Study of
Autism Consortium, 1998; Philippe et al., 1999; Risch et al., 1999; Schellenberg et al.,
2006; Trikalinos et al., 2006; Vincent et al., 2000). A patient with karyotype 46XY,
t(2;16)(q21;q13) and autistic characteristics was studied to identify the translocation
breakpoint in the chromosomal 2q21 region. The breakpoint at chromosome 2q21 was
narrowed to a region of only 80kb and a potential candidate gene within this region was
identified.
In summary, this work found an association between Autistic Disorder and the
MET gene rs1858830 C variant. Two alterations were identified in NLGN4X that are
associated with Autistic Disorder and further studies provided information about the
cellular localization and morphology associated with these alterations. Finally, this work
identified a candidate gene, C2orf27A, located in the 2q21 chromosomal region, that may
be involved in Autism Spectrum Disorder.
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Chapter 1

FURTHER EVIDENCE THAT THE rs1858830 C VARIANT IN THE PROMOTER
REGION OF THE MET GENE IS ASSOCIATED WITH AUTISTIC DISORDER.

Introduction
Autistic Disorder is a neurodevelopmental disorder characterized by social
impairments, communication impairments, repetitive behaviors, and a restricted pattern
of interests and behaviors (Folstein and Mankoski, 2000; Lamb et al., 2005; Muhle,
Trentacoste, and Rapin, 2004; Rutter, 2005; Veenstra-VanderWeele and Cook, 2004).
The prevalence of Autistic Disorder is one in 500 children, and onset can occur as early
as three years of age (Fombonne, 1999; Yeargin-Allsop et al., 2003). Pervasive
Developmental Disorder (PDD), which encompasses autistic signs and symptoms that
vary in severity, has a much higher prevalence of one in 166 children (Fombonne, 1999;
Herba et al., 2008; Yeargin-Allsop et al., 2003). The term Autism Spectrum Disorder
(ASD) includes these two diagnoses and Pervasive Developmental Disorder-Not
Otherwise Specified (PDD-NOS). This high prevalence of both Autistic Disorder and
PDD has increased the desire to identify the causes that may lead to these disorders.
Genome-wide linkage scans have attempted to identify potential regions within
the human genome where genes that cause autism may be located. These studies have
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identified various chromosomal regions (2q, 4, 15q, 16p, 17q, 19, and 22q) that are
putative locations of autism genes (Barrett et al., 1999; Herba et al., 2008; Philippe
et al., 1999; Risch et al., 1999; Schellenberg et al., 2006), including a region at
chromosome 7q that is associated with autism (Ashley-Koch et al., 1999; Folstein and
Rosen-Sheidley, 2001; Gutknecht et al., 2001; International Molecular Genetic Study of
Autism Consortium, 1998; Trikalinos et al., 2006; Vincent et al., 2000). The MET gene
is located within this region, at chromosome 7q31, and a report by Campbell et al. (2006)
found a variant within the promoter region, rs1858830 C, to be associated with autism in
two separate cohorts (individuals in the cohorts had diagnoses that ranged from autism to
ASD).
Recently, there have been other studies identifying a correlation between the MET
gene and autism. A positive correlation between the MET rs1858830 C allele variant and
autism was found in a third cohort with diagnosis falling in the range of ASD (Campbell
et al., 2008). A study by Sousa et al. (2009) found a positive correlation between rs38845
in the MET gene and autism in two cohorts with diagnosis falling in the range of ASD,
but was unable to find a correlation between the rs1858830 C allele variant and autism.
These combined results include five unrelated cohorts that show a positive association
between the MET gene and autism.
The MET gene is known to play a role in the metastasis of a variety of cancers
and in mediating hepatocyte growth factor/scatter factor signaling in peripheral organ
development and repair (Blume-Jensen and Hunter, 2001; Gheradi et al., 2003; Park et
al., 1987). Recent studies also indicate that MET contributes to the development of the
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cerebral cortex and cerebellum (Campbell et al., 2007; Ierci, Forni, and Ponzetto, 2002;
Powell, Mars, and Levitt, 2001; Powell et al., 2003). The cerebral cortex and cerebellum
both have been shown to be disrupted during development in individuals with autism
(Bauman and Kemper, 2005). MET is also involved in immune function and
gastrointestinal repair (Campbell et al., 2007; Tahara et al., 2003). The involvement of
MET in gastrointestinal repair is of some interest due to the fact that some individuals
with autism also exhibit gastrointestinal problems (Campbell et al., 2006).
In the present study, we tested for an association of the MET rs1858830 C variant
with Autistic Disorder and PDD in two unrelated cohorts. The study utilized cohorts of
patients with Autistic Disorder and PDD from South Carolina and Italy, respectively.
The cohort of individuals diagnosed with Autistic Disorder is very unique because it
represents a narrowly defined population within Autism Spectrum Disorder.

Materials and Methods
This study included a South Carolina cohort composed of 174 patients (110
Caucasians, 56 African Americans, and eight unknowns) between the ages of five and 21
years with Autistic Disorder from the South Carolina Autism Project (SCAP) (Schroer et
al., 1998). The South Carolina cohort diagnoses were established utilizing the Autism
Diagnostic Interview-Revised (ADI-R) or the Childhood Autism Rating Scale (CARS)
tests. An Italian cohort composed of 65 patients ranging in diagnosis from Autistic
Disorder (n = 14) to PDD (n = 51) was also studied. The Italian cohort was composed of
Caucasian patients that met the ADI-R and/or the Autism Diagnostic Observation
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Schedule (ADOS) criteria for Autistic Disorder or PDD. In both cohorts, all patients had
negative results for high-resolution chromosome analyses and FMR1 molecular testing.
Four SCAP patients carried balanced chromosomal rearrangements that did not involve
any known autism locus.
The South Carolina control cohort consisted of 180 Caucasian males, 89 African
American males, 11 Caucasian females, and 89 African American females. The Italian
control cohort consisted of 55 Caucasian males and 71 Caucasian females. In both
cohorts all of the control individuals were 18 years of age or older, and none of these
individuals ever demonstrated any features of developmental delay or autistic traits.
Screening for the MET promoter rs1858830 variant was conducted using genomic
DNA amplified using primer metF (gatttccctctgggtggtg) and primer metR
(caagccccattctagtttcg) in a polymerase chain reaction (PCR). Amplification was carried
out in 20 µL reactions containing 105 ng genomic DNA, 2µL of 1 µM of each
appropriate primer, 0.08 µL of dNTPs, 2 µL of 5X PCR buffer, 1µL DMSO, 0.2 µL Hot
Start Antibody, and 0.2 µL Go Taq DNA polymerase. Amplification conditions
consisted of an initial denaturation of 95oC for five minutes, then 30 cycles consisting of
a denaturation step at 95oC for 30 seconds, annealing temperature of 55oC for 30 seconds,
and an extension at 72oC for 60 seconds. A final extension at 72oC lasted for seven
minutes. PCR products were examined on a 1.5% agarose gel containing ethidium
bromide and visualized under ultraviolet light. After digesting overnight at 37oC in a 20
µL reaction containing 1X Buffer, 1 µL Eag I enzyme, and 10 µL PCR product, the DNA
was analyzed on a 3.5% TBE agarose gel containing ethidium bromide and visualized
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under ultraviolet light. Individuals with the genotype GG had fragments of 378 base
pairs, 240 base pairs, and 34 base pairs. An individual with the genotype CC had
fragments of 412 base pairs and 240 base pairs, and an individual with the genotype GC
had all of these fragments.
The Hardy-Weinberg equilibrium and odds ratio tests were performed for the
different groups using Microsoft Excel (Redmond, OR). Chi-square tests comparing the
allelic and genotypic proportions between cases and controls were performed using Epi
InfoTM 3.4.3 (Atlanta, GA). Family-based association testing was performed using an
additive model with the FBAT program (Horvath, Xu, and Laird, 2001).

Results
To characterize the rs1858830 C variant in the promoter region of the MET gene
(Campbell et al., 2006), we used restriction endonuclease digestion. The chromosome 7q
region containing the variant was amplified by polymerase chain reaction (PCR) and the
amplicon was digested with the restriction endonuclease Eag I (Figure 1.1). Genotype
frequencies for the case and control cohorts from the South Carolina and Italian
populations are shown in Tables 1.1 and 1.2. All case and control cohorts were found to
be in Hardy-Weinberg equilibrium.
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a

b

Figure 1.1 MET PCR amplification and Eag I endonuclease digestion. (a) MET
PCR product 650 bp. Lane 1 is a 100 base pair marker. Lane 2 and 3 are PCR
products using primers metF and metR. (b) Digestion of MET PCR product with
endonuclease Eag I. Lane 1 is a 100 base pair marker. Lane 2 contains the
product of an individual with genotype GG for the rs1858830 C variant in the
promoter region of MET. Lanes 3, 4, and 6 contain the digested products of
individuals with the genotype GC for the rs1858830 C variant in the promoter
region of MET. Lane 5 contains the digested DNA amplicon of an individual with
the genotype CC for the rs1858830 C variant in the promoter region of MET.
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Table 1.1 MET rs1858830 allele genotypes
Cohort

GG

GC

CC

Total

South Carolina Autistic Disorder

55

91

28

174

South Carolina Controls

159

164

46

369

Italian Autistic Disorder

5

8

1

14

Italian PDD

12

21

18

51

Italian Controls

34

65

27

126

1

2

Results from comparison of these groups with the appropriate controls are as follows:
χ = 6.7, df = 2, P = 0.04 and 2χ2 = 3.7, df = 2, P = 0.16.

1 2

Table 1.2 MET rs1858830 allele genotypes by type of family
Cohort

GG

GC

CC

Total

South Carolina cases from simplex families1

50

78

26

154

South Carolina cases from multiplex families

5

13

2

20

South Carolina Controls

159

164

46

369

1

Results from the comparison of cases from simplex families with the SC controls are as follows:
χ2 = 5.5, df = 2, P = 0.06.

The genotypic proportions within the South Carolina cohort, consisting of patients
diagnosed with Autistic Disorder, were found to be significantly different from the South
Carolina controls (χ2 = 6.7, df = 2, P = 0.04; Table 1.1). There was no significant
difference in genotypic proportions between the Italian controls and the PDD patients
within the Italian cohort (Table 1.1). This association approached significance for South
Carolina cases from the simplex families (χ2 = 5.5, df = 2, P = 0.06) as compared to
controls (Table 1.2).
In the South Carolina cohort, a significant association with Autistic Disorder was
found when comparing the CC or the CG genotype to the GG genotype (OR= 1.64; 95%
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CI = 1.12-2.40; χ2 = 6.5, df = 1, P = 0.01). This association was also significant for cases
from simplex families (OR = 1.58; 95% CI = 1.06-2.34; χ2 = 5.1, df = 1, P = 0.02). In the
Italian cohort, no significant association with PDD was found when comparing the CC or
the CG genotype to the GG genotype (OR = 1.20; 95% CI = 0.56-2.56; χ2 = 0.2, df = 1, P
= 0.64).
Allelic frequencies for the South Carolina and Italian patient and control groups
are found in Table 1.3. The frequency of the C allele variant was found to be
significantly increased in South Carolina Autistic Disorder patients as compared to South
Carolina controls (χ2 =5.8, df = 1, P = 0.02). There were no significant differences found
in the allele frequencies between the Italian patient and control groups.

Table 1.3 MET rs1858830 allele frequencies
Cohort

G

C

South Carolina Autistic Disorder

0.58

0.42

South Carolina Controls

0.65

0.35

0.64

0.36

Italian PDD

0.44

0.56

Italian Controls

0.53

0.47

1

2

Italian Autistic Disorder
3

Results from comparison of these groups with the appropriate controls are as follows:
χ = 5.8, df = 1, P = 0.02; 2χ2 = 1.3, df = 1, P = 0.25; and 3χ2 = 2.2, df = 1, P = 0.14.

1 2

Family-based association testing (Horvath, Xu, and Laird, 2001) indicated no
overtransmission of the C allele variant to affected individuals (Z = 0.10 and P = 0.92) in
the South Carolina cohort families (Horvath, Xu, and Laird, 2001). The allele frequency
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of the MET rs1858830 G allele was 0.59 and the C allele was 0.41. Seventy-five of 174
families (43%) were informative for this analysis.

Discussion
We found an association between the MET rs1858830 promoter C variant and
Autistic Disorder in our South Carolina cohort of patients. This study is the fourth
independent cohort to find correlation between the MET rs1858830 C allele variant and
autism. Campbell et al. (2006, 2008) found a positive correlation between the MET
rs1858830 C allele variant and autism in a cohort of 204 Italian families with autism, a
US cohort of 539 families, and an unrelated cohort of 101 families from the US. Sousa et
al. (2009) found a correlation between the MET gene rs38845 variant in two autistic
cohorts (a 335 IMGSAC family cohort and an 82 family autistic Italian cohort), but no
correlation with the rs1858830 C allele variant and autism. These cohorts included
patients with either Autistic Disorder or PDD-NOS.
There is a possibility that the association observed between the MET rs1858830 C
allele variant and Autistic Disorder in the South Carolina cohort is due to population
stratification. As shown in Table 1.4, Caucasians within this cohort have a higher
frequency of the C allele variant and also comprise a larger proportion of cases. To
further examine this, a Cochran-Mantel-Haenszel test was run using SAS Version 9.2
(The SAS Institute, Cary, NC) to analyze the association of the CC and CG genotypes
versus the GG genotype and Autistic Disorder while controlling for racial group (OR=
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1.48, 95% CI = 0.99-2.21; χ2 = 3.7, df = 1, P = 0.05). While stratification may have some
influence on the new borderline significant results, it appears that the CC and CG
genotypes remain associated with Autistic Disorder in the South Carolina cohort,
especially in Caucasians.
Table 1.4 MET rs1858830 allele genotypes by racial group in the South Carolina population
Allele
Population
Allele genotypes
frequency
Racial
Cohort
G
C
GG
GC
CC
Total
Group
African
Autistic
0.69
0.31
26
25
5
56
American
Disorder
Autistic
Caucasian
0.51
0.49
26
61
23
110
Disorder
Autistic
Other
0.69
0.31
3
5
0
8
Disorder
African
Control
0.73
0.27
96
67
15
178
American
Caucasian

Control

0.58

0.42

63

97

31

191

Our study did not find any association of the MET rs1858830 C allele with PDD
within the Italian cohort. This may be evidence that there is no correlation between PDD
and the C allele variant. This result may also be due to the small sample size in this
cohort. Although both the South Carolina and Italian cohorts contained approximately
twice as many controls as cases, we would have needed at least 300 cases and 600
controls to have 80% power to detect an allele frequency difference of ten percentage
points between the two groups (Power and Precision, Biostat, Englewood, NJ).
However, smaller sample sizes can give you an indication of potential significant
findings with larger sample sizes.
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The involvement of MET signaling in interneuron development along with its
involvement in gastrointestinal repair is a possible key to its association with Autistic
Disorder. MET is a receptor for hepatocyte growth factor (HGF) in the forebrain. HGF
provides trophic support, stimulates axonal outgrowth, and enhances neuronal
differentiation (Tahara et al., 2003). Alterations in MET signaling may lead to a
disruption in the involvement of MET with HGF leading to alterations in GABAergic
neuron development in the forebrain (Levitt, Eagleson, and Powell, 2004; Powell et al.,
2001, 2003). Reduced MET signaling could possibly explain the epilepsy and atypical
sleep patterns found in some individuals with Autistic Disorder. Epilepsy and atypical
sleep patterns may indicate an imbalance in the glutamatergic (excitatory) projection
neurons and GABAergic inhibitory interneurons in the neocortex (Levitt, Eagleson, and
Powell, 2004; Powell et al., 2003; Tuchman and Rapin, 2002). This is probably
significant due to this balance of excitation-inhibition being relatively conserved across
mammalian species (Levitt, Eagleson, and Powell, 2004).
MET is involved in the normal development of the cerebellum and cerebral cortex
(Campbell et al., 2007; Ierci, Forni, and Ponzetto, 2002; Powell et al., 2003; Powell,
Mars, and Levitt, 2001). Mice with alterations in MET expression have altered
organization of the cerebellum and cerebral cortex. Altered organization of the
cerebellum and cerebral cortex has also been found in individuals with autism (Bauman
and Kemper, 2005). This indicates that a reduction in MET signaling may lead to
abnormalities in the organization of the cerebellum and cerebral cortex.
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HGF also serves as a critical regulator of intestinal wound healing (Tahara et al.,
2003). A previous study indicates that HGF and MET together may function in the repair
of gastrointestinal abnormalities (Tahara et al., 2003). The rs1858830 C variant found in
the promoter region of MET may lead to an altered interaction of HGF and MET
resulting possibly in their inability to correct intestinal abnormalities. This may also
account for the gastrointestinal problems found in individuals with Autistic Disorder.
In conclusion, this study reinforces an association with Autistic Disorder and the
MET rs1858830 C allele variant as noted by Campbell et al. (2006). The results from our
study indicate that MET may play a stronger role in individuals with Autistic Disorder as
compared to other diagnoses contained within the spectrum of autism. Our results, in
conjunction with other studies (Campbell et al., 2006, 2008; Sousa et al., 2009), suggest
the rs1858830 C variant in the promoter region of the MET gene is likely a significant
risk factor for Autistic Disorder.
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Chapter 2

CELLULAR LOCALIZATION AND FUNCTIONAL ANALYSIS OF TWO
ALTERATIONS IDENTIFIED IN NLGN4X

Introduction
Autism is a disorder associated with developmental delay, impairments in
communication and social skills, and abnormal patterns of behaviors and interests.
Autistic Disorder is a type of Autism Spectrum Disorder (ASD). Autism Spectrum
Disorder classification includes Asperger syndrome and Pervasive Development
Disorder-Not Otherwise Specified (Rutter, 2005). Autistic Disorder occurs before the
age of three years and varies in the degree of severity of social skills, behavior, and
cognition. The male to female ratio is 4:1 (Ylisaukko-oja et al., 2005). The exact nature
of the male predisposition for autism has not been identified, but several previously
identified alterations of the X chromosome are associated with autism (Jamain et al.,
2003; Laumonnier et al., 2004; Ylisaukko-oja et al., 2005). Specifically, Jamain et al.
(2003) and Laumonnier et al. (2004) identified mutations in NLNG4X in patients
diagnosed with ASD.
NLGN4X, which is located at chromosome Xp22.3, is a member of the neuroligin
family. The neuroligin family in humans is comprised of five neuroligin genes: NLGN1
(3q26), NLGN2 (17p13), NLGN3 (Xq13), NLGN4X (Xp22.3), and NLGN4Y (Yq11.2)
(Chih et al., 2004 and Talebizadeh et al., 2004). This family of genes is involved in the
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production of cell-adhesion molecules essential for the formation and stability of
functional synapses (Talebizadeh et al., 2004). Alterations in the NLNG4X gene have
been associated with ASD (Jamain et al., 2003; Ylisaukko-oja et al., 2005).
Alterations in NLGN4X may lead to the abnormal development of synapses,
resulting in altered communication processes in the brain and cognitive development.
Phenotypes such as impairments in communication and social skills, and deficits in
cognition resulting from altered communication processes and cognitive development of
the brain, are observed in individuals with ASD (Jamain et al., 2003; Ylisaukko-oja et al.,
2005). The higher incidence of Autistic Disorder in the male population does support the
involvement of genes located on the X chromosome (Ylisaukko-oja et al., 2005). Further
research is needed to understand how alterations in NLGN4X may lead to Autistic
Disorder. This study is designed to identify any alterations in NLGN4X in patients with
Autistic Disorder and how these alterations may lead to the Autistic Disorder phenotype.

Materials and Methods
Subjects
This study included 204 subjects with Autistic Disorder from 178 different
families. DNA samples from these Autistic Disorder patients and their families were
provided by the South Carolina Autism Project (SCAP). The SCAP is composed of
individuals diagnosed specifically with Autistic Disorder using the Autism Diagnostic
Interview-Revised test, Bayley Scales of Infant Development, and the Stanford-Binet
Intelligence Scale: Fourth Edition (Schroer et al., 1998).
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Case Reports
Autism 17702
This individual is a male that was diagnosed with autism at 5.5 years of age. His
height was measured at the 40th percentile, weight was greater than the 98th percentile,
and his head circumference was at the 70th percentile. The individual’s mother smoked
during pregnancy and had several episodes of vaginal blood spotting. He was delivered
by cesarean birth at 40 weeks gestation. He only spoke a few words at the age of two
then stopped speaking until age four. His gross motor skills were noted to be clumsy and
he had outbursts of anger that involved tearing things, yelling, and episodes of cursing.
He has a history of ear infections with the placement of tubes in his ears but no other
significant childhood illness. He was hospitalized once due to his aggressive behavior.

Autism 15627
This individual is a female that was diagnosed with autism at the age of four years
and eight months. Her height and weight were both above the 95th percentile and her
head circumference was measured at the 60th percentile. She is the older of two children
and her sibling is reported to be normal. Her mother had cryosurgery on her cervix
during the third week of pregnancy and developed hypertension during the last trimester
of pregnancy. She was delivered vaginally at 38 weeks gestation after induction. She
has a history of ear infections and had tubes placed in her ears and an adenoidectomy.
She had normal vocabulary development, but there were concerns about her cognitive
and social development around 18 months of age. She was very hyperactive, provided
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inappropriate responses to questions, played inappropriately with toys, and did not play
well with other children.

Mutation Screening
Alterations in patients Autism 17702 and Autism 15627 were identified in
NLGN4X using by single-strand conformation polymorphism (SSCP) analysis in the
SCAP cohort (unpublished data by Gao and Schwartz). The alteration c. 775 C>T was
confirmed in patient Autism 17702 and the alteration c. 864 G>A was confirmed in
patient Autism 15627 by sequence analysis using primers 1 and 2 and primers 3 and 4
(Table 2.1), respectively. Amplification was carried out in 50µL reactions containing
105 ng genomic DNA, 5µL of 10µM of each appropriate primer, 0.08µL of dNTPs, 10µL
of 5X PCR buffer, and 0.5µL Go Taq DNA polymerase. Amplification conditions
included an initial denaturation of 95oC for 5 minutes, then 30 cycles consisting of a
denaturation step at 95oC for 30 seconds, optimal annealing temperature for 30 seconds,
extension at 72oC for 30 seconds, followed by a final extension at 72oC for 7 minutes.
PCR products were purified using a Qiagen kit (GE Healthcare Life Sciences,
Buckinghamshire, United Kingdom). Samples were sequenced using the recommended
standard procedure for the MegaBASE 1000 (GE Healthcare Life Sciences,
Buckinghamshire, United Kingdom). Sequencing results were analyzed using a SeqMan
program which is part of the DNASTAR Lasergene 7 Program (DNASTAR, Inc.,
Madison, WI).
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Table 2.1 NLGN4X primer list
Primer Name
Primer 1
Primer 2
Primer 3
Primer 4
Primer 5
Primer 6
Primer 7
Primer 8
Primer 9
Primer 10

Sequence (5’-3’)
ACCAAAAATCTCTTGTGTTCT
TTCTTGGTTCAGGGTATTTGC
TTCTGTCCTGTGTTTCATTTG
AGGATCTGGGGGTCGTCTGG
TTTTTAAGTACCGGTGACCAG
CCTCTGAGTAGTGGGACAGG
CACCGCCCTGTCCAGCTAGA
AGGATCTGGGGGTCGTCTGG
AGAAGGCCATCATTCAGAGC
CATGTTGCAGCCGACCTT

Polymorphism Study
One thousand normal X chromosomes were screened to determine if either of the
c. 775 C>T or c. 865 G>A point mutations were a rare single nucleotide polymorphism
(SNP). The alteration c. 775 C>T was tested using polymerase chain reaction (PCR) and
enzymatic digestion. Genomic DNA from control individuals was amplified using
primers 5 and 6 (Table 2.1). The amplification was carried out in a 50µL reaction
containing 105ng genomic DNA, 5µL of 10µM of each appropriate primer, 0.8µL of
dNTPs, 10µL of 5X PCR buffer, and 0.5µL of Go Taq DNA polymerase. Amplification
conditions consisted of an initial denaturation of 95ºC for 5 minutes, then 30 cycles
consisting of a denaturation step at 95ºC for 30 seconds, annealing temperature of 60ºC
for 30 seconds, and an extension at 72ºC for 60 seconds. A final extension at 72ºC lasted
for 7 minutes. PCR products were examined on an agarose gel containing ethidium
bromide and visualized under ultraviolet light. The PCR product was digested overnight
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at 37ºC with the restriction endonuclease Mnl I. The digestion reaction of 20µL
contained 2µL of 10X buffer, 1µL of Mnl I enzyme, and 10µL of PCR product. The
alteration created an enzymatic site not present in normal sequences (Figure 2.2). This
band difference was observed on a 1.5% TBE agarose gel with ethidium bromide that
was allowed to run for 2 hours.
The screening of the controls for the c. 865 G>A alteration was conducted using
allelic specific primers. If the altered allele is present it would be the only allele to
amplify because primer 7 (Table 2.1) is specific for the alteration. A primer set for a
control gene was used with every PCR to ensure that the PCR conditions were optimal.
The amplification was carried out in a 50µL reaction containing 105ng genomic DNA,
5µL of 10µM of each appropriate primer, 0.8µL of dNTPs, 10µL of 5X PCR buffer, and
0.5µL of Go Taq DNA polymerase. Products obtained after amplification were
electrophoresed on a 1.5% agarose gel with ethidium bromide and analyzed under
ultraviolet light.

Family Analysis
Family members of the patient with the c. 865 G>A alteration were available for
testing. An analysis was conducted with genomic DNA of family members of the patient
utilizing PCR and enzymatic digestion. The amplified region had an extra HpyCH4III
enzymatic site if the alteration was present. Amplification was carried out with primers 9
and 10 (Table 2.1). The amplification conditions were denaturation at 95oC for 5 minutes
followed by 30 cycles of denaturation at 95oC for 30 seconds, annealing at 60oC for 30
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seconds with an extension of 72oC for 30 seconds, followed by a final extension at 72oC
for 7 minutes. The amplification was carried out in a 50µL reaction containing 105ng
genomic DNA, 5µL of 10µM of each appropriate primer, 0.8µL of dNTPs, 10µL of 5X
PCR buffer, and 0.5µL of Go Taq DNA polymerase. The PCR product was digested
with HpyCH4III overnight at 37oC in a 20µL reaction containing 2µL of 10X Buffer,
2µL of 10X BSA, 2µL of 10X Spermidine, and 10uL of PCR product, the digested
product was analyzed on a 1.5% TBE agarose gel containing ethidium bromide and
visualized under UV light. To confirm the presence of both alleles in the father, the DNA
amplicon from PCR, utilizing primers 9 and 10, was subcloned into the pCR 2.1 vector
(Invitrogen Corporation, Carlsbad, CA). Positive colonies were isolated and sequenced
to obtain a single strand sequence. Colonies were sequenced using the recommended
standard procedure for the MegaBASE 1000 (GE Healthcare Life Sciences,
Buckinghamshire, United Kingdom). Sequencing results were analyzed using a SeqMan
program which is part of the DNASTAR Lasergene 7 Program (DNASTAR Inc.,
Madison, WI).

NLGN4X Construct
Wild type NLGN4X was obtained from the clone MHS1011-7509691, that was
purchased from OPEN BIOSYSTEMS. This clone contained the full-length NLGN4X
cDNA. The full-length cDNA was amplified from the plasmid by PCR with cDNAF
(caccatgtcacggccccaggga) and cDNAR (tactctagtggtggaatgtcc)primers. Amplification
was carried out in 25µL reactions containing 1µL of the clone, 2.5µL of 10µM of each
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primer, 4µL of 2.5mM dNTPs, 2.5µL of 10X PCR buffer, and 0.5µL PFU DNA
polymerase. Amplification conditions included an initial denaturation step at 95°C for 2
minutes, then 30 cycles consisting of a denaturation step at 95°C for 30 seconds, 55°C
optimal annealing temperature for 30 seconds, extension at 72°C for 4 minutes and 30
seconds, followed by a final extension at 72°C for 10 minutes. PCR samples were placed
on ice and one unit of GoTaq was added to each sample. Samples were incubated at
72°C for 10 minutes. The PCR product was isolated by gel extraction. The product was
purified using the Qiagen Gel Extraction kit. The purified PCR product was cloned into
the pcDNA3.1D/Vs-His-TOPO expression vector following the manufacturer’s protocol
(Invitrogen Corporation, Carlsbad, CA). The construct was sequenced to confirm the
proper reading frame using the standard procedure for the 3730 DNA Analyzer (Life
Technologies Corporation, Carlsbad, CA) . Sequencing results were analyzed using the
SeqMan program which is part of the DNASTAR Lasergene 7 Program (DNASTAR,
Inc., Madison, WI).

c. 775 C>T and c. 865 G>A Constructs
The two alterations, c. 775 C>T and c. 865 G>A, were created using Stratagene’s
QuikChange II Site-Directed Mutagenesis kit. The pcDNA3.1D/Vs-His-+ NLGN4X
construct was used as a template for these reactions. The c. 775 C>T alteration was
created with primer c. 775 C>T (gctggggcctcccgtgtcagctgt) and primer c. 775 C>T
antisense (acaggctgacacgggaggccccagc). The c. 865 G>A alteration was created with
primer c. 865 G>A (cctgtccagctgggcaatgaactaccagcc) and primer c. 865 G>A antisense
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(ggctggtagttcattgcccagctggacagg). A reaction for each alteration was conducted in a total
volume of 50µL containing 5µL of 10X reaction buffer, 10ng of dsDNA template,
1.25µL of c. 775 C>T primer or c. 865 G>A primer at 100ng/µL, 1.25µL of c. 775 C>T
antisense primer, 1.25µL c. 865 G>A antisense primer at 100ng/µL, 1µL 10µM dNTP
mix, and 40.5µL of double distilled water, and 1µL of Pfu Ultra HF DNA polymerase
(2.5U/µL). The reaction proceeded in a thermal cycler at 95°C for 30 seconds, then 12
cycles of 95°C for 30 seconds, 55°C for one minute, and 68°C for five minutes. After
cycling was complete the products were placed on ice for two minutes. One microliter of
the restriction enzyme Dpn I (10U/µL) was added to the PCR products and this reaction
was allowed to incubate for one hour at 37°C. The Dpn I treated DNA was transformed
in XL1-Blue Supercompetent cells following standard transformation procedure. The
transformations were spread on plates containing 100mg of ampicillin and LB agar.
Colonies were picked and grown in liquid cultures and plasmids were purified using
Quiagen Midi prep kit. The constructs were sequenced to confirm the mutation using the
standard protocol for the 3730 DNA Analyzer (Life Technologies Corporation, Carlsbad,
CA) . Sequencing results were analyzed using the SeqMan program which is part of the
DNASTAR Lasergene 7 Program (DNASTAR, Inc., Madison, WI).

Cell Line Maintenance
The PC-12 cell line was obtained from American Type Culture Collection
(ATCC) and is a rat pheochromacytoma cell line derived from a cancerous adrenal gland
(American Type Culture Collection, Manassas, VA). The cells were grown at 37°C with
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5% CO2. Standard procedures for passage of the cell line were followed. These
protocols included removal of cells twice per week to obtain a 1:2 ratio of cells to cell
culture media (500mL F12-K, 75mL Horse serum, 15mL fetal bovine serum (FBS), 5mL
of penicillin, 5mL of 10,000 units per mL streptomycin, and 5mL of 200mM Glutamine
(L-Glut)). This included removing the growth media from the cells, washing with 10mL
of Phosphate Buffered Saline (PBS) (Sigma), and adding 3mL of Trypsin+EDTA
(Sigma). After three minutes, the 3mL of Trypsin+EDTA (Sigma) was removed from the
cells and 7mL of growth media is added back to the cells. Nine mililiters of this mixture
was removed that could be used for further studies or discarded. Thirteen mililiters of
growth media was added back to the remaining 1mL of cell mixture and the cells were
allowed to continue growing at 37°C at 5% CO2.

PC-12 Cell Transfection
PC-12 cells were transfected with constructs using Neuromag in a 24-well format.
The PC-12 cells were seeded at a density of 150,000 cells per well in 1% plating media
(50mL DME and 0.5mL of FBS). Poly L-Lysine coating (100µL of poly L-Lysine and
10mL of PBS) of 500µL was added to each of the wells, and the plate was incubated at
37°C overnight. Cells were then transfected with 1µg of the appropriate vector with the
NeuroMag (Boca Scientific, Boca Raton, FL) transfection reagent. After adding the
vector/transfection mixture at a ratio of 1µg:3.5µL (DNA:NeuroMag) to the cells, the
cells were placed on a magnet for 20 minutes on a level surface. The plates were placed
back in the incubator at 37°C for five hours. After five hours of incubation, 400µL of
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warm growth media was added to each well. The cells were incubated at 37°C overnight
and then seeded onto 18 mm diameter, 1.0 mm thick microscope cover glass slips
(Fisher) that had a poly L-Lysine and laminin coating (10mL of PBS, 100µL of 10mg/µL
poly L-Lysine, and 100µL of 1mg/µL laminin). Nerve growth factor (Sigma) treatment
was added to the appropriate cells on slips to allow the cells to grow extensions that
mimic neurites. The slips were then placed back a 37°C incubator for 36-48 hours.
Forty-eight hours later the cells were used in immunofluorescence studies or protein was
harvested from the cells.

Fluorescence Microscopy
PC-12 cells transfected with V5-tagged NLGN4X, V5-tagged c. 775 C>T
NLGN4X, or V5-tagged c. 865 G>A NLGN4X were stained with anti-V5 mouse
monoclonal antibody (Invitrogen Corporation, Carlsbad, CA) to visualize the V5-tagged
protein. Dapi (4;6-diamidino-Z-phenylindole) (Molecular Probes) was used to stain the
nucleus of each cell. Rhodamine Phalloidin (Molecular Probes) was used to stain the
cytoskeleton of each cell. The anti-V5 mouse monoclonal antibody was visualized by the
use of an Alexa Fluor 594 goat anti-mouse Immunoglobulin G secondary antibody
(Invitrogen Corporation, Carlsbad, CA).
The growth media was aspirated off the transfected cells and the cells were
washed twice in PBS. The cells were fixed by adding 1mL of 4% para-formaldehyde to
each well for 30 minutes. Triton X-100, at a concentration of 0.1%, was added to each
well for five minutes to make the cells permeable. The Triton X-100 was aspirated off
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and the cells were washed twice with PBS. Quenching solution (1.02g sodium acetate in
50mL PBS) was added to each well to remove background fluorescence. Five hundred
microliters of Quench was added for seven and half minutes, and then aspirated off and
500µL more of Quench was added for an additional seven and half minutes. The Quench
was removed and cells were washed with block (2% horse sera and 0.4% BSA in PBS).
This first 500µL of block was removed and then 500µL of block was added back and
allowed to incubate with cells for 30 minutes at room temperature. At the end of 30
minutes the primary antibody diluted 1:400 in PBS was added and allowed to incubate at
room temperature for one hour with the cells. The primary antibody was then aspirated
off and the cells were washed three times with block. Each rinse was allowed to incubate
at room temperature for five minutes. The secondary antibody was diluted 1:2000 in
blocking solution and 488 Phalloidin was added to the cells and allowed to incubate for
one hour at room temperature. The secondary antibody and 488 Phalloidin were removed
and the cells were washed three times with block with incubation at room temperature for
five minutes after each rinse. The Dapi stain, at a concentration of 1:1000, was added to
each well and incubated for five minutes. It was then aspirated off and the cells were
rinsed with PBS. Each slip was then mounted with eight microliters of anti-fade ProLong
Gold (Invitrogen Corporation, Carlsbad, CA) mounting media onto microscope slides.
The slides were viewed with the Zeiss Ax10 inverted Fluorescence Microscope. Images
were captured with the AxioCam MRCS and analyzed with the AxioVision Release 4.6.3
software. Data were stored and analyzed in Microsoft Excel (Redmond, WA). Unpaired
t-tests were used to compare the length and number of neurite extensions on the cells. An
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F-test was run before the t-test to check if the variances were equal, and this information
was then used to run the t-test.

Western Analysis
Protein was isolated from PC-12 cells with 1X Lamelli’s sample buffer and then
boiled for 5 minutes at 95°C. The protein was loaded on a precast 4 to 20% gradient
SDS-PAGE gel (Pierce, Rockford, IL). The gel was allowed to run for one hour and
thirty minutes at 100 volts. The protein was transferred to a nitrocellulose membrane
using a Bio-Rad Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad, Hercules, CA). After
transfer the membrane was rinsed in Tris-Buffered Saline and Tween 20 (TBST) twice
and placed in block (5% nonfat dry milk dissolved in TBST) for one hour at room
temperature. At the end of the one hour block the membrane was rinsed in TBST once
and incubated with a primary antibody overnight at 4°C with continual agitation. The
primary antibody was removed and the membrane was rinsed with TBST for one hour,
while changing the TBST three times during the hour. The membrane was incubated
with the appropriate secondary antibody for one hour at room temperature with constant
agitation. The SuperSignal®West Dura Extended Duration Substrate (Pierce, Rockford,
IL) was used for chemiluminescent detection.

Cell Fractionation
Cell fractionation was performed to confirm cellular localization of the V5-tagged
protein. This was conducted utilizing the FractionPREP Cell Fractionation system
following the manufacturer’s protocol (BioVision, Mountain View, CA). In brief,
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transfected PC-12 cells were fractionated by exposure to a corresponding cell fraction
buffer and then the fraction was separated by centrifugation. Cells were washed with
PBS, 1.1 mL of Cytosol Extraction buffer with Protease Inhibitor Cocktail (PIC) and
DTT were added to the cells, and then the 60-mm plates that cells were grown on were
scraped. This mixture was transferred to an eppendorf tube and allowed to incubate on
ice for 30 minutes. After the incubation, the samples were centrifuged for 10 minutes
and the resulting supernatant was the cytosolic faction. The remaining pellet was
resuspended in 1.1 mL of Membrane Extraction Buffer-A with PIC and DTT. After the
pellet was resuspended, 5.5µL of Membrane Extraction buffer-B was added and samples
incubated on ice for one minute. Samples were centrifuged for five minutes and the
resulting supernant was the membrane/particulate fraction. The remaining pellet was
resuspended in 500µL of Nuclear Extraction Buffer with PIC and DTT. The samples
were kept on ice for 40 minutes and vortexed every 10 minutes. After the incubation,
samples were centrifuged for 10 minutes and the resulting supernatant was the nuclear
fraction. The remaining pellet was the cytoskeletal fraction that then was dissolved in 1X
Lamelli sample buffer. Ten percent of each fraction was loaded onto a 4 to 20% precast
gradient SDS-PAGE gel (Pierce, Rockford, IL). The cell fractions for the c. 775 C>T
alteration were loaded onto an additional 4 to 20% precast gradient SDS-PAGE gel
(Pierce, Rockford, IL) at 50% of each fraction since amounts of protein were not
detectable using only 10% of the fraction.
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Results
The SCAP cohort was screened to identify any alterations in NLGN4X, a gene
previously associated with ASD. The screen identified two missense mutations from
unpublished data by Gao and Schwartz that had not been reported previously (Table 2.2).
These alterations were confirmed by sequence analysis (Figure 2.1). The two alterations
were not observed in 1000 random X control chromosomes, thus indicating that the two
alterations were rare single nucleotide polymorphisms.

Table 2.2 NLGN4X alterations identified in the mutation screen
Type of
Alteration
Alteration
Patient
Domain
Mutation
Base Pair
Amino Acid
Extracellular
17702
Missense
c. 775 C>T
p. S258P
noncatalytic
acetylcholinesterase
homolog
Extracellular
15627
Missense
c. 865 G>A
p. A288T
noncatalytic
acetylcholinesterase
homolog
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Figure 2.1 Sequence identification of NLGN4X alterations and normal NLGN4X. (a)
Sequence of c. 775 C>T NLGN4X alteration and normal NLGN4X sequence. (b)
Sequence of c. 865 G>A NLGN4X alteration and normal NLGN4X sequence.

As genomic DNA from the family of the patient with the c. 865 G>A alteration
was available, an analysis was conducted to determine if this was a de novo mutation.
The screening of the family determined that the father carries the alteration. The father
also appears to have both the altered and a normal allele (Figure 2.2). Primers for the Y
chromosome confirmed that the sample also contains material from this chromosome
indicating that the sample is from a male (Figure 2.2). Sequence analysis confirmed that
the father does have one normal allele and one altered allele. The father may have a
duplication on his X chromosome that contains the NLGN4X gene or may have two X

36

chromosomes. This may also be a result of sample contamination. New samples from
this family are needed for further studies and to rule out sample contamination.
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Figure 2.2 Family analysis of the c. 865 G>A alteration identified in NLGN4X. (a)
Agarose Electrophoresis picture of individuals digested with HpyCH4III. The c. 865
G>A change creates an enzymatic site resulting in products that are 61 and 43 base
pairs in size. If the change is not present the product is undigested resulting in a
product that is 104 base pairs. The lanes contained the following samples: 1) Patient
with c. 865 G>A NLGN4X alteration, 2) Mother of patient, 3)Father of patient, 4)
Brother of patient, 5) Random male control, 6) Random female control. (b) The arrow
indicates the 225 base pairs amplicon from PCR analysis to identify Y chromosome
material. The lanes contained the following samples: 1) Marker, 2) Father of patient,
3) Brother of patient, 4) Random male control. PCR confirms that the DNA from the
father contains Y chromosome material.

Protein structure analysis indicates the alterations p. S258P and p. A288T lead to
an alteration in protein structure (Table 2.3). These alterations are located within the
extracellular noncatalytic acetylcholinesterase homolog domain. The extracellular
noncatalytic acetylcholinesterase domain is involved in the presynaptic binding of
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neurexin (Laumonnier et al., 2004). Splice site analysis indicates that these alterations do
not increase splicing or alter a splice site.

Table 2.3 NLGN4X protein prediction
Protein Prediction
Program
Pmut
iPTREE
PANTHER
Polyphen
SIFT

Protein Prediction Website

p. S258P

p. A288T

http://mmb2.pcb.ub.es:8080/PMut/

Pathological

Neutral

http://210.60.98.19/IPTREEr/iptree.htm

Negative

Negative

http://www.pantherdb.org/

Deleterious

Deleterious

http://genetics.bwh.harvard.edu/pph/

Possibly
Damaging

Benign

http://sift.jcvi.org/

Not Tolerated

Not Tolerated

The bioinformatic results obtained indicated that the two identified alterations in
NLGN4X had potentially damaging effects which led us to study these alterations in vivo
(Table 2.4). The alterations in NLGN4X and wild type NLGN4X were transfected into the
PC-12 cell line to determine cellular localization and function. PC-12 cells were
transfected with wild type NLGN4X, c. 775 T>C NLGN4X, c. 865 G>A NLGN4X, or lac
Z (control). Western analysis also indicated that the NLGN4X protein was of appropriate
size and transfected PC-12 cells were expressing the protein (Figure 2.3). There does
appear to be a difference in the size of the NLNG4X protein expressed in vitro as
compared to the protein expressed in vivo. This may be a result of posttranslational
modifications that may have taken place in vivo.
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PC-12 cell line transfections were visualized using a Zeiss Ax10 inverted
Fluorescence Microscope (Figures 2.4 and 2.5). The cells transfected with wild type
NLGN4X appear similar to untransfected cells and cells transfected with lacZ. The cells
transfected with wild type NLGN4X have a normal cell body, appropriately mimic
neurite formation after treatment with nerve growth factor, and form an appropriate
number of neurite extensions (after treatment with nerve growth factor). The wild type
protein was observed at the cell membrane and was found in the neurite extensions and
observed in the structures that mimic synapses. These structures would be the correct
location based on NLGN4X involvement in synapse formation. PC-12 cells transfected
with mutant c. 775 C>T NLGN4X were very different in appearance when compared to
cells transfected with wild type NLGN4X, lac Z, or untransfected cells. Cells expressing
the mutant c. 775 C>T NLGN4X protein have an abnormal cell body that appeared larger
in size. The cell body appears more like a flattened body than the normal cell body that
has the stretched appearance from the growth of the neurite extensions. The neurite
extensions of these cells were significantly shorter (t-test P-value=1.58E-12 and Figure
2.5) and had significantly less neurite extensions (after treatment with nerve growth
factor; t-test P-value=5.8E-05) then the wild-type cells. The altered protein did not
localize to the cell membrane nor into the extensions the same way as the cells
transfected with wildtype NLGN4X (Figures 2.4 and 2.5). The altered protein appears to
stay localized close to the nucleus. PC-12 cells transfected with the c. 865 G>A
NLGN4X were different from cells transfected with wildtype NLGN4X, lac Z, or
untransfected cells. The cell body was larger and abnormal in shape. The cell body had
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more of a blob shape instead of the normal stretching shape observed in neuronal cells.
These cells did not form proper neurite extensions. The extensions were shorter in length
and fewer in number (Figure 2.6). The altered protein was transported to the cell
membrane and into the neurite extensions, but the neurite extensions do not appear to
form correctly.
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lac Z (120 kDa)
in vitro (118kDa)
in vivo (118kDa)

Figure 2.3 NLGN4X western analysis. In vitro expression from the T7 translation of
the expression construct used in the transfections and in vivo expression from cell
lysate of transfected PC-12 cells. a. The lanes contained the following proteins: in
vitro NLGN4X protein (1), in vitro c. 775 C>T NLNG4X protein (2), in vitro c. 865
G>A NLGN4X protein (3), in vitro lac Z protein (4) and in vivo protein of NLGN4X
(2 and 6), in vivo c. 775 C>T NLGN4X (3 and 7), in vivo c. 865 G>A NLGN4X (4
and 8), and in vivo lac Z (5).
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Figure 2.4 Cellular localization and function of NLGN4X transfected PC-12 cells. (a)
NLGN4X (red) is found throughout the cytoplasm, cell membrane, and neurite
extensions. The cellular outline is depicted by phalloidin staining of actin (green) and
the nucleus is depicted by the dapi stain (blue). (b) NLGN4X with c. 775 C>T
alteration (red) is found in the cytoplasm but does not appear to be at the cell
membrane or in the neurite extensions. (c) NLGN4X with c. 865 G>A alteration (red)
is found in the cyptoplasm, cell membrane, and in neurite extensions. (d) lac Z (red) is
found in the cytoplasm, cell membrane, and in neurite extensions.
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Figure 2.5 Cellular localization and function of NLGN4X transfected PC-12 cells.
Yellow arrow indicates synapse formation. (a) NLGN4X (red) is found throughout the
cytoplasm, cell membrane, and neurite extensions. The cellular outline is depicted by
phalloidin staining of actin (green) and the nucleus is depicted by the dapi stain (blue).
(b) NLGN4X with c. 775 C>T (red) alteration is found in the cytoplasm but does not
appear to be at the cell membrane or in the neurite extensions. (c) NLGN4X with c.
865 G>A (red) alteration is found in the cyptoplasm, cell membrane, and in neurite
extensions. (d) lac Z (red) is found in the cytoplasm, cell membrane, and in neurite
extensions.
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Figure 2.6 Average neurite length of NLGN4X transfected cells. PC-12 cells
transfected with wild type NLGN4X are labeled as wt, cells transfected with c. 775
C>T are labeled as t775c, cells transfected with c. 865 G>A are labeled as g865a, and
cells transfected with lac Z are labeled as lacz. The star above t775c indicates that the
neurite lengths for these cells were significantly shorter than cells transfected with
wild type NLGN4X (t-test P-value=1.58E-12).

An endogenous Golgi apparatus protein in PC-12 cells was also used to study
cellular localization. The Golgi plays a role in modifying and sorting some proteins. If
there was a problem modifying or sorting these altered NLNG4X proteins, the protein
may be localizing in the Golgi apparatus and not properly transported in the cell.
The GS28 Golgi protein was stained with chicken anti-mouse Alexa fluor 488
(Molecular Probes) after cells were transfected with either wild type NLGN4X, mutant c.
775 C>T NLGN4X, mutant c. 865 G>A NLGN4X, or with lac Z. Colocalization in the
Golgi would exist if the protein of interest was located in the Golgi. There does not
appear to be any colocalization of the endogenous Golgi protein and wild type NLGN4X,
the two mutants, or lac Z (Figure 2.7).
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Figure 2.7 GS28 cellular localization in NLGN4X transfected PC-12 cells. (a)
NLGN4X (red) is found throughout the cytoplasm, cell membrane, and neurite
extensions. The Golgi specific protein, GS28, is depicted by green and the nucleus is
depicted by the dapi stain (blue). (b) NLGN4X with c. 775 C>T alteration (red) was
found in the cytoplasm but does not appear to be in the Golgi apparatus. (c) NLGN4X
with c. 865 G>A alteration (red) was found in the cyptoplasm, cell membrane, and in
neurite extensions but does not appear to be located in the Golgi apparatus. (d) lac Z
(red) was found in the cytoplasm, cell membrane, and in neurite extensions and not in
Cell fractionation studies were conducted to further determine the location of
NLGN4X in the PC-12 cells (Figures 2.8 and 2.9). This study supported previously
observed cellular localization of NLGN4X wild type, c. 775 C>T NLGN4X altered
protein, c. 865 G>A NLGN4X altered protein, and lac Z. The amount of wild type
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NLGN4X protein in each cellular fraction compared to the amount of c. 775T>C altered
NLGN4X protein in each cellular fraction was different. This indicated a difference
between the wild type NLGN4X protein localization and the c. 775T>C NLGN4X
alteration protein localization. There was a greater percentage (32.5% vs. 24.6%) of c.
775 T>C NLGN4X in the cytosol fraction, less in the membrane/particulate fraction
(45% vs. 59.1%), and more in the cytoskeletal fraction (10% vs. 2.7%) as compared to
wild type NLNG4X. The amount of wild type NLGN4X in each fraction when compared
to the amount of c. 865 G>A NLGN4X in each fraction was different for some fractions
but the same for others. The percentages for the cytosol fraction from the c. 865 G>A
NLGN4X (18.2% vs. 24.6%) mutant were less than the wild type, the membrane
fractions for the mutant and wild type were similar. There was much less c. 865 G>A
NLNG4X (1.5% vs. 13.6%) protein in the nuclear fraction than the wild type, and there
was no detectable protein for the cytoskeletal fraction from the c. 865 G>A mutant that
was treated with nerve growth factor. Western analysis confirmed that cell fractions for
different parts of the cell contained known proteins for the different cell fractions (Figure
2.8).
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Figure 2.8 NLGN4X cell fractionation. Ten percent of each fraction for each
transfection was loaded onto a protein gel and probed with the V5 antibody. Cytosol
fraction for untransfected PC-12 cells, PC-12 cells transfected with NLGN4X, c. 775
C>T NLGN4X, c. 865 G>A NLGN4X, and lac Z. Membrane/particulate fraction for
untransfected PC-12 cells, PC-12 cells transfected with NLGN4X, c. 775 C>T
NLGN4X, c. 865 G>A NLGN4X, and lac Z. Nuclear fraction for untransfected PC-12
cells, PC-12 cells transfected with NLGN4X, c. 775 C>T NLGN4X, c. 865 G>A
NLGN4X, and lac Z. Cytoskeletal fraction for untransfected PC-12 cells, PC-12 cells
transfected with NLGN4X, c. 775 C>T NLGN4X, c. 865 G>A NLGN4X, and lac Z.
Below each cellular fraction is the protein gel probed with a specific antibody for each
cellular fraction to confirm that each fraction is specific for its location. The cytosol
fraction was probed with the GAPDH antibody, the membrane/particulate fraction was
probed with the Na+/K+-ATPaseα1 antibody, the nuclear fraction was probed with the
lamin B antibody, and the cytoskeletal fraction was probed with the α tubulin
antibody.
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Figure 2.9 NLGN4X cell fractionation of c. 775 T>C. Previously loaded 10% of the
c. 775 T>C fractions were not visible after Western analysis. The experiment was
repeated loading 50% of each fraction from the c. 775 T>C transfection and probed
with the V5 Antibody. Each lane is indicated as having nerve growth factor (NGF) or
not having NGF treatment. Each lane is indicated with the representative cellular
fraction.

Discussion
The high ratio of males to females (4:1) diagnosed with autism has lead to the
assumption that causative genes for ASD are located on the X chromosome. Studies
have resulted in the identification of genes on the X chromosome involved with Autistic
Disorder (Centers for Disease Control and Prevention, 2009; Ylisaukko-oja et al., 2005).
This study screened an autistic population looking for possible alterations in one of these
genes on the X chromosome, NLGN4X. This study presents the identification of two
novel NLGN4X alterations (c. 775 C>T and c. 865 G>A), in vivo protein expression for
these two alterations, and cellular localization of these two alterations.
The c. 775 C>T NLGN4X alteration is a de novo alteration found in a male
proband. The c. 865 G>A NLGN4X alteration was identified in a female proband and is
possibly of paternal inheritance. This is perplexing since the digestion and sequence
analyses of the father indicate that he contains the altered allele and the normal allele. It
is expected that the father would only contain one allele for this gene since it is located
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on the X chromosome. The father may have a XXY karyotype, be mosaic, or it is
possible that the sample is contaminated with the proband’s DNA. Testing of the father’s
sample did confirm that it contained material from the Y chromosome.
The autistic population screened for this study was from the SCAP (Schroer et al.,
1998). This population represents a group of individuals diagnosed with Autistic
Disorder only. The participants were identified using the Autism Diagnostic InterviewRevised to test adaptive function. Cognitive skills were tested using Bayley Scales of
Infant Development and Stanford-Binet Intelligence Scale: Fourth Edition (Schroer et al,
1998).
The NLGN4X gene belongs to the neuroligin family (Chih et al., 2004). This
family of genes is composed of neuronal cell-surface proteins located in the synaptic
structures (Chih et al., 2004 and Talebizadeh et al., 2004). Every member contains a
conserved domain that is critical for presynaptic neurexin binding, a transmembrane
domain, and a short cytoplasmic tail (Talebizadeh et al., 2004). Their location in the
glutamatergic synapses suggests a role in targeting excitatory synapses. Previous studies
also indicate their involvement in the ability to trigger the formation of functional
presynaptic elements (Benson et al., 2000; Scheiffele, 2003; Waites et al., 2005). This
leads to axon specialization, and their involvement in synaptogenesis (Scheiffle et al,
2000). NLGN4X plays an important role in the normal function of all these processes.
Abnormal function in autistic individuals may lead to an alteration in synapses or abolish
the formation of synapses required for communication processes.
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PC-12 cells treated with nerve growth factor can mimic neuronal cells and their
formation of neurites. Functional cellular analysis from PC-12 cells treated with nerve
growth factor demonstrates that cells transfected with c. 775 C>T or c. 865 G>A (altered
NLGN4X protein) do not form proper neurite extensions as compared to cell transfected
with wild type NLGN4X protein and controls. The cells form extensions that are shorter
in length and fewer in number. The protein that results from the c. 775 C>T alteration
does not appear to traffic properly through the cell to reach the cell membrane or the
location for neurite extension formation. The NLGN4X protein containing the c. 865
G>A alteration expressed in PC-12 appears to localize to the same locations as wild type
NLGN4X but does not form neurite extensions of equal length or number. In cells
transfected with wild type NLGN4X and lac Z, a control protein, a structure that mimics
a synapse, can be observed. These structures are not observed in cells with either the c.
775 C>T or c. 865 G>A altered NLGN4X protein. These results indicate that these novel
alterations identified in NLGN4X may lead to abnormal formation of synapses or possibly
the absence of synapse formation. Both of these novel alterations are located in the
extracellular noncatalytic acetylcholinesterase homolog domain of NLGN4X. This is the
major extracellular domain of NLGN4X and all neuroligins that mediates binding to
neurexin. This is the domain in neuroligins that also forms homomultipliers which are
structural associations that are important for function (Comoletti et al., 2003; Dean et al.,
2003).
Alterations in the extracellular noncatalytic acetylcholinesterase homolog domain
could lead to altered association with neurexin which could result in synapses not being
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formed and/or poor stability. The abnormal formation of synapses in the individuals with
these alterations may lead to their diagnosis of autism. Further study of brain
development and the presence of abnormal synapse formation are needed to more clearly
understand how these alterations affect cognitive problems observed in these individuals.
This study screened a cohort of individuals diagnosed with Autistic Disorder and
a cohort of controls and identified two alterations in NLGN4X. The c. 775 T>C NLGN4X
alteration is a de novo alteration, while both alterations were determined to not be rare
single nucleotide polymorphisms. Studies were conducted that observed aberrant cellular
localization and cell morphology due to the presence of the two NLGN4X alterations
expressed in PC-12 neuronal cell line. Fluorescence microscopy determined that
neuronal cells expressing the two alterations identified in NLGN4X did have altered cell
morphology. Cellular localization studies also identified a difference between the
location of the altered NLGN4X protein within the cell and the location of wild type
NLGN4X in the cytosol, membrane, nucleus, and cytoskeleton of the cell.
Future studies are needed to determine if the father of the patient with the c. 865
G>A NLGN4X alteration has a karyotype of XXY or if his sample used for these studies
was contaminated with the patient’s sample. Future studies are also needed to further
understand NLGN4X’s role in synapse formation and cognitive function.
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Chapter 3

IDENTIFICATION OF CANDIDATE GENES FOR AUTISM SPECTRUM
DISORDER IN A PATIENT WITH A t(2;16)(q21q13) TRANSLOCATION

Introduction
Autism Spectrum Disorder (ASD) is a collection of neurodevelopmental disorders
that affect development, communication, social skills, behaviors, and interests of affected
individuals. Autistic Disorder is the most severe and attention deficit disorders are the
least severe of the disorders in the spectrum. Autism Spectrum Disorder affects one in
110 children (Centers for Disease Control and Prevention, 2009). This high prevalence
has increased the need to identify causative genes for ASD.
Genome-wide linkage scans have previously identified chromosomal locations
that may contain causative genes for ASD. These studies identified that the 2q
chromosomal region potentially contains causative gene(s) for ASD (Barrett et al., 1999;
Herba et al., 2008; Philippe et al., 1999; Risch et al., 1999; Schellenberg et al., 2006).
These genes could be identified by mapping the breakpoints of cytogenetically visible
chromosomal aberrations in individuals with ASD.
An individual with autistic features and a 46XY, t(2;16)(q21;q13) karyotype was
studied. Currently there are no known causative genes for ASD located in the 2q21
chromosomal region that contains the translocation breakpoint. This study narrowed the
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translocation breakpoint on chromosome 2q21 to an area of 80kb and identified a
putative causative gene in this region.

Materials and Methods
Case Report
CMS5326 is a male whose height was measured at the 2nd percentile and head
circumference was measured at the 90th percentile at 31 years of age. At his birth he had
a “pin hole” anal opening that was covered with a membrane. He has autistic features
that include repetitive behaviors and poor social skills. His karyotype was determined to
be 46, XY, t(2;16)(q21;q13).

Molecular Cytogenetics
BAC clones were identified and selected by searching for the breakpoint region
on chromosome 2q21 using the NCBI
(http://www.ncbi.nlm.nih.gov/genome/guide/human) database. BAC clones were
obtained from BACPAC (Chori BACPAC Resources). DNA was purified using Qiagen
Mini-Prep colums. DNA was labeled by incorporation of digoxigenin-11-dUTP or
biotin-16-dUTP (Roche) by nick translation using DNA polymerase (Life Technologies).
Labeled probes were combined with 50X human Cot-1 DNA (Gibco-BRL) and a
chromosome 2 specific labeled centromeric alphoid probe to a final concentration of
20ng/µL. This product was then denatured at 76°C for 10 minutes and allowed to
preassociate at 37°C for 20 minutes before hybridization.
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Metaphase chromosome spreads were obtained from lymphoblastoid cells and
FISH was performed using previously described methods (Ross et al., 1997; Vervoort et
al., 2002). Replication banding was also performed in conjunction with FISH to provide
secondary confirmation of chromosome identity. Labeled probes were visualized with
rhodamine-labeled anti-digoxigenin and chromosomes were counterstained with DAPI.
Images were examined under a Zeiss Axiphot fluorescence microscope equipped with
FITC, DAPI, and triple band pass filter sets.

Microarray Analysis
Agilent Human Genome CGH 244 microarray analysis (Agilent Technologies)
was used to determine if a deletion existed within the breakpoint region. This technique
uses a two-color process to measure DNA copy number changes in an experimental
sample relative to a reference sample. The process of dye-swapping was utilized for each
experimental sample to provide confirmation of results. The reference sample was
normal commercially available genomic DNA. The manufacturer’s protocol was
followed, which included digestion of one microgram of genomic DNA by adding 5.9µL
Digestion Master Mix (2µL nuclease-free water, 2.6µL 10X buffer, 0.2µL of 10µg/µL
acetylated BSA, 0.5µL of 10U/µL Alu I, and 0.5µL of 10U/µL Bsa I). Digestion
reactions were incubated at 37ºC for two hours and then transferred to 65ºC for 20
minutes to inactivate the restriction endonucleases. Samples were then labeled
individually with cyanine 3-dUTP and cyanine 5-dUTP. Labeling was conducted by
adding 21µL of Labeling Master Mix (2µL nuclease-free water, 10.0µL of 5X buffer,
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3µL of 1.0mM cyanine 3-dUTP or 3µL of 1.0mM cyanine 5-dUTP, and 1µL ExoKlenow fragment) to each sample. Samples were allowed to incubate at 37ºC for two
hours and then transferred to 65ºC for ten minutes to inactivate the enzyme. Labeled
genomic DNA was diluted by adding 430µL of 1X TE to each reaction and purified as
follows. Each sample was loaded onto a Microcon YM-30 filter (Agilent Technologies),
centrifuged for ten minutes, and the flow-through was discarded. Appropriate purified
cyanine 5-labeled sample and purified cyanine 3-labeled samples were combined and
5µL of 1mg/mL of Cot-1 DNA, 11µL of Agilent 10X Blocking Agent, and 55µL of
Agilent 2X Hybridization buffer were added to each sample. Samples were incubated at
95ºC for three minutes and then they were incubated at 37ºC for 30 minutes. A gasket
slide in the Agilent SureHyb chamber (Agilent Technologies) was loaded with 490µL of
sample. The assembled slide chamber was placed in a rotator rack in a hybridization
oven at 65ºC with rotation for 24 hours. After this incubation, samples were washed in
Oligo aCGH Wash Buffer 2 (Agilent Technologies) at 37ºC overnight. Next, the slides
were washed and removed from the assembly in Oligo aCGH Wash Buffer 1 (Agilent
Technologies). Slides were scanned using the GenePix 4000B scanner (Agilent
Technologies) and the Feature Extraction software v9.5 (Agilent Technologies) was used
to extract microarray TIFF images.
The Agilent Human Genome CGH 244 Microarray was found to be probe poor in
the 2q21 chromosomal area, so we utilized a different microarray that had better coverage
in this area (Agilent Technologies). The Affymetrix® Genome-Wide Human SNP
Nsp/Sty 6.0 array was utilized to identify if any deletions existed in the translocation
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breakpoint. This array contains 906,600 thousand unique SNPs probes and 945,826 copy
variant probes. A genomic DNA control (Reference Genomic DNA 103) provided with
the the Affymetrix array was utilized as the experimental positive control. The DNA
control was also used to assess the quality of the sample genomic DNA. Manufacturer’s
protocols were followed that included digesting 250ng of sample genomic DNA with Sty
I restriction endonuclease in a Sty I digestion master mix and a separate digestion of
sample genomic DNA with Nsp I restriction endonuclease in a Nsp I digestion master
mix (11.55µL AccuGENE® water, 2µL 10X NE buffer, 0.2µL 10mg/mL BSA, and 1µL
10U/µL Sty I or Nsp I). Samples were digested for 120 minutes at 37°C and then the
enzyme was denatured at 65°C for 20 minutes. Digested samples (19.75µL of each
sample) were ligated using the Sty Adaptor or Nsp Adaptor (Affymetrix) in a ligation
reaction containing 2.5µL 10X T4 DNA Ligase Buffer, 0.75µL of 50µM Adaptor Sty I or
Adaptor Nsp I, and 2µL of 400U/µL T4 DNA Ligase. Samples were ligated at 16°C for
180 minutes. After ligation 10µL of each sample was amplified using TITANIUM Taq
DNA polymerase using the primer provided by the manufacturer (Affymetrix).
Amplification products were visualized on a 2% TBE gel under ultra violet light to verify
that the product had a size between 200 base pairs and 1100 base pairs. The amplified
sample for each enzyme was pooled together and purified using the manufacturer’s
supplied magnetic beads and filter plate and then each sample was quantitated.
Amplification products were fragmented using 5µL of 0.1U/µL of Fragmentation
Reagent (Affymetrix) at 37°C for 35 minutes. Fragmentation was visualized on a 4%
TBE agarose gel under ultra violet light. Fragmented samples were then labeled using
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2µL of 30mM DNA labeling Reagent and 3.5µL of 30U/µL TdT enzyme (Affymetrix) at
37°C for four hours. Each reaction was then loaded onto a Genome-Wide Human SNP
Array 6.0 and allowed to hybridize for 18 hours. The array was then washed and stained
in the Fluidics Station 450 (Affymetrix). The array was then scanned with the GeneChip
Scanner 3000 7G (Affymetrix). Results were analyzed using the Genotyping Console 2.1
program (Affymetrix).

Quantitative Real-Time PCR
RNA was extracted from transformed human lymphoblastoid cell lines. RNA
was purified by treatment with two units of TURBOTM DNase (Ambion) for every 50µg
of RNA for 30 minutes at 37°C. RNA was further purified by precipitation with 7.5M
lithium chloride solution (Ambion). Quantitative Real-Time PCR was conducted using
the iScriptTM One-Step RT-PCR kit with SYBR® Green (Bio-Rad, Hercules, CA) on the
iCycler iQTM Real-Time PCR system (Bio-Rad, Hercules, CA). Experimental primer
sequences used for amplification were: FKSG30-RT-F-5’- cacaaagcttaaaggaagtgaaa-3’,
FKSG30-RT-R-5’- ttcttcttcaatagccataaaatcttc-3’, MGC50273-F-5’aagaggacgcagcctgtcta-3’, and MGC50273-R-5’-cgctgcttctggggtaca-3’. The NEPH2F (5’gggccatcagagctaaagacc-3’) and NEPH2R (5’- cttgggggaagtggaggttta-3’) primers
amplified exon 16 of the NEPH2 reference gene. Cycling conditions were as follows:
denaturation at 95ºC for five minutes followed by the two-step amplification cycles at
95ºC for 10 seconds and 58ºC for 30 seconds repeated 40 times. All samples were
analyzed in quadruplicate and the data obtained was analyzed with the iCycler iQTM
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software to generate a standard curve for each gene and calculate fluorescence generated
from the experimental primer pairs relative to the NEPH2 gene using the comparative Ct
method (Bio-Rad, Hercules, CA).

PCR Analysis
DNA from BAC clones RP11-25F5, RP11-611E16, and RP11-890E24 were
amplified using primers listed in Table 3.1. Amplification was carried out in 50µL
reactions containing 105 ng DNA, 5µL of 10µM of each appropriate primer, 0.8µL of
dNTPs, 10µL of 5X PCR buffer, and 0.5µL Go Taq DNA polymerase. Amplification
conditions included an initial denaturation of 95oC for 5 minutes, then 30 cycles
consisting of a denaturation step at 95oC for 30 seconds, optimal annealing temperature
(Table 3.1) for 30 seconds, extension at 72oC for 30 seconds, followed by a final
extension at 72oC for 7 minutes. PCR products were visualized on an agarose gel
containing ethidium bromide under ultraviolet light.
Table 3.1 Translocation primer list
Primer Name
Primer Sequence
Annealing Temperature
A Forward
gataccgctgtgctcgtcattg
55ºC
A Reverse
cagttcccgcccagccaggtcta
55ºC
B Forward
gcacagaggggcaggagtagttca
55ºC
B Reverse
agttttcccctgtggcggtagag
55ºC
C Forward
aggccaacagttcccagagtgacc
58ºC
C Reverse
ccttccgggattagaccttgag
58ºC
D Forward
aggccaacagttcccagagtgacc
58ºC
D Reverse
ccttcccgggattagaccttgag
58ºC
E Forward
gggccctttctccaacactat
55ºC
E Reverse
aaaaaccctcccccaaaacag
55ºC
F Forward
tcccacattcagtttctcagtttg
55ºC
F Reverse
ccagcagctacaggtaaggaata
55ºC
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Results
CMS 5326 had a karyotype identified to be t(2;16)(q21;q13). BAC clones RP11611E16, RP11-890E24, and RP11-25F5 were identified to be located in the translocation
region on chromosome 2q21 and were used in FISH analysis to map the translocation
breakpoint critical region (Figure 3.1). The boundaries of the chromosome breakpoint
region were established with BAC probe RP11-611E16, which was proximal to the
breakpoint (signal was on the normal and derivative chromosome 2), and BAC probe
RP11-25F5, which was distal to the breakpoint (signal on the normal chromosome 2 and
derivative chromosome 16) (Figure 3.1). BAC clone RP11-890E24 spans both BAC
clones RP11-611E16 and RP11-25F5 according to the NCBI database. However, this
clone did not span the breakpoint by FISH analysis. Rather it was found to be distal to
the breakpoint (signal was found on the normal chromosome 2 and derivative
chromosome 16) (Figure 3.1). At this point a deletion was suspected in the patient that
carried this translocation and FISH analysis was followed by microarray analysis to
determine if a deletion was present.
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a

c

b

RP11-25F5

RP11-611E16

RP11-890E24

Figure 3.1 FISH analysis of chromosome 2 breakpoints involved in a
t(2;16)(q21;q13). (a) FISH analysis of distal probe RP11-25F5 (green). The white
arrow indicates a signal on normal chromosome 2 and the yellow arrow indicates a
signal on derivative chromosome 16. (b) FISH analysis of proximal probe RP11611E16 (green). Yellow arrows indicate a signal on normal and derivative
chromosome 2. (c) FISH analysis of distal probe RP11-890E24 (green). The white
arrow indicates a signal on normal chromosome 2 and yellow arrow indicates a signal
on derivative chromosome 16. A centromeric control probe for chromosome 2 is
shown in red.

Comparative Genomic Hybridization (CGH) was utilized to determine if a
deletion in the translocation breakpoint region on chromosome 2q21 existed.
Comparative Genomic Hybridization is a molecular-cytogenetic technique that can detect
copy number changes in an individual’s DNA. Balanced reciprocal translocations and
inversions are not detected since these alterations do alter the copy number of DNA. The
Agilent Human Genome CGH 244 Microarray was utilized first. A change in dosage
was not observed at the translocation breakpoint 2q21 (Figure 3.2). However, there were
only a few probes from the microarray that covered the translocation breakpoint region
for chromosome 2. The Affymetrix® Genome-Wide Human SNP Nsp/Sty 6.0
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microarray was then utilized. This array has over one million unique probes that cover
the human genome (906,600 unique SNPs probes and 945,826 copy variant probes).
Probe coverage for the translocation breakpoint region was good but no deletion or loss
of heterozygosity was identified in this region (Figure 3.3).

a

Figure 3.2 Agilent Human Genome CGH 244 Microarray Analysis. (a) Translocation
breakpoint region for chromosome 2q21. Blue circles represent probes from the
microarray. Probes past the outer green line represent a duplication or gain of gene
dosage. Probes past the outer red line represent a deletion or loss of gene dosage.
There were not any duplication or deletions identified.

60

a

b

Figure 3.3 Affymetrix® Genome-Wide Human SNP Nsp/Sty 6.0 Microarray
Analysis. (a) Copy number variant probes in the 2q21 breakpoint critical region.
There is no loss of heterozygosity identified. (b) SNPs probes in the 2q21 critical
region. A duplication or deletion is not identified.

Quantitative Real-Time PCR (QRT-PCR) was conducted to identify a deletion
within the region on chromosome 2q21 that contained the breakpoint. The boundaries for
the breakpoint on chromosome 2q21 that were identified from FISH analysis were used
to choose the genes for QRT-PCR analysis. Genes at the proximal and distal end of the
breakpoint were chosen for this analysis. Primers for FKSG-30 and MGC50273 were
used for expression analysis. Results from this expression analysis indicated a possible
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duplication for this region but statistical error is high for this experiment and microarray
analysis does not support these results (Figure 3.4).

Figure 3.4 Quantitative RT-PCR. Quantitative RT-PCR analysis indicates possible
duplication of FKSG-30 and MGC50273 between the translocation patient
(CMS5326) and two control patients. Quantitative RT-PCR was performed in
quadruplicate.

The results obtained from microarray analysis did not support results obtained
from Quantitative RT-PCR analysis. In order to confirm that the FISH probes contained
the correct sequence, each FISH probe (RP11-611E16, RP11-890E24, and RP11-25F5)
was amplified by PCR to confirm that deletions were not present in any probe used and to
confirm that each probe contained the indicated sequence. These results indicated that
the areas of the probes that were amplified do not contain any deletions and indicate that
the probes likely contain the appropriate sequence information (Figure 3.5). Further
analysis of the FISH probe location indicates that C2orf27A is the only identified possible
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gene in the 80 kb overlap region of the proximal (RP11-611E16) and distal (RP11890E24) FISH probes (Figure 3.6).

Figure 3.5 PCR Amplification of FISH probes. Blue hexagons indicate primer pairs
that were used in the amplification of each FISH probe and their location in the 2q21
translocation region. The yellow oval depicts the area that RP11-611E16 covers in the
2q21 translocation breakpoint region. The blue oval depicts the area that the RP11890E24 covers in the 2q21 translocation breakpoint region. The green oval depicts the
area covered by RP11-25F5 in the 2q21 translocation breakpoint region. The boxes
indicate the location of these probes in base pair on chromosome 2 in human genome
build 36.1.
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Figure 3.6 Schematic representation of the location of FISH probes and genes.
The location of FISH probes and genes found within this region are represented to
scale.

Discussion
This study was unable to isolate the translocation breakpoint in the patient with
ASD and karyotype 46,XY,t(2;16)(q21;q13). We were able to narrow the translocation
breakpoint region at 2q21 to an area of 80kb by FISH. The boundaries of the
translocation breakpoint identified by FISH analysis were utilized to analyze gene
expression. Genes were chosen from the proximal end and distal end (FKSG-30 and
MGC50273) of the breakpoint region (Figure 3.4). Quantitative RT-PCR indicated a
possible duplication of these two predicted genes. These results were not supported by
data obtained from microarray analysis.
There is only one gene, C2orf27A, contained within this 80kb region that may
contain the breakpoint. C2orf27A (chromosome 2 open reading frame 27A) is a
predicted protein coding gene but very little is known about this gene. POTEKP
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(FKSG30) and C2orf27B (chromosome 2 open reading frame 27B, MGC50273) were the
genes utilized for RT-PCR analysis. These two genes lie just outside the 80 kb region
that may contain the breakpoint. Very little is known about the predicted protein coding
gene C2orf 27B (MGC50273). Bera et al. (2002) identified the POTE gene on
chromosome 21q11.2 and a paralog of this gene is located at 2q13-q22. POTEKP,
located at 2q21.1, is the prostate, colon, lung, breast, ovary, and pancreas ankyrin domain
family, member K, pseudogene (Bera et al., 2002). The POTE gene is involved in
carcinogenesis, localized on the inner side of the plasma membrane, and is mainly
involved in facilitating membrane interactions (Bera et al.,2002; Das et al., 2007; Resh,
2006). More studies are needed to confirm that POTEKP is actually a pseudogene. It is
possible that this gene is still producing a protein and abnormalities in the protein may
account for the phenotype observed in the patient with this translocation. Abnormalities
of POTEKP could lead to improper cell to cell communication in neurons. This may
account for the social impairments and repetitive behaviors observed in Autism Spectrum
Disorder.
The TUBA3D (tubulin, alpha 3d) gene is located at chromosome 2q21.1 and is a
member of the TUBA3 family. This gene is located outside the RP11-611E16 FISH
probe. The exact function of this gene is not known, but it is speculated to be involved in
formation of the hippocampus and the cortex because abnormalities in this gene lead to
lissencephaly in humans (Keays et al., 2007; Nanda et al., 2008). Lissencephaly is an
abnormality in the formation of the brain and results in intellectual disability (ID) and
possibly epilepsy (Francis et al., 2006). Mutations in the mouse homolog Tuba1 are
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associated with impaired neuronal migration (Keays et al., 2007). The identification of
chromosome 2q by genome-wide scans as a putative location for Autism Spectrum
Disorder genes and the location of this gene within the translocation area in an individual
with autistic features indicate a need for future studies involving alterations in TUBA3D
and ASD.
C2orf27A is the most likely candidate gene causing the autistic features and
macrocephaly observed in this patient due to its location within the 80kb region that
contains the chromosomal breakpoint. Array data does not indicate a deletion or
duplication within this region. Future studies are needed to identify the cause of the
features observed in this patient. Further analyses of C2orf27A, putative causative gene,
may identify alterations in this gene in this patient.
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CONCLUSIONS

Autism Spectrum Disorder includes a wide range of disorders and phenotypes.
This implies the involvement of many genes that lead to these disorders and phenotypes.
Many studies are currently being conducted to identify causative genes for Autism
Spectrum Disorder and several genes have been identified. The studies presented here
associated Autistic Disorder with the rs1858830 C variant of MET, which is a putative
causative gene for Autistic Disorder, identified two alterations in NLGN4X (putative
causative gene for ASD), provided cellular localization and function for these alterations,
and identified a putative causative genes, C2orf27A, for ASD.
The first study screened a cohort of individuals diagnosed with Autistic Disorder
and controls to confirm an association of the rs1858830 C variant of the MET gene with
Autistic Disorder. The results obtained showed an association between the rs1858830 C
variant and Autistic Disorder.
NLGN4X is involved in synapse formation and stabilization (Talebizadeh et al.,
2004; Ylisaukko-ofa et al., 2005) and has previously been shown to be associated with
Autism Spectrum Disorder (Jamain et al., 2003; Laumonnier et al., 2004). The second
study identified two alterations in NLGN4X, one alteration is a de novo alteration, c. 775
C>T. The inheritance of the c. 865 G>A alteration is unclear due to the proband’s father.
A resample is needed to clarify significance of this alteration in the father. The two
alterations were determined not to be rare single nucleotide polymorphisms. Functional
cellular studies and cellular localization studies were conducted to determine the effects
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of these alterations in vivo. The analysis conducted with PC-12 cells indicates that both
alterations affect the normal function of NLGN4X. Cells transfected with altered
NLGN4X did not form as many neurties per cell as compared to cells transfected with
wild type NLGN4X. Cells transfected with altered NLGN4X produced cells with neurites
that were significantly shorter than cells transfected with wild type NLGN4X. These
results indicate that NLGN4X may have a significant role in cognitive development.
The third study narrowed the translocation breakpoint region to 80kb located on
chromosome 2q21 by FISH analysis in a patient with a 46XY, t(2;16)(q21;q13)
karyotype. We attempted to identify the breakpoint at chromosome 2q since this region
had previously been identified as possibly containing genes that cause Autism Spectrum
Disorder. The individual who carries this t(2;16)(q21;q13) translocation has autistic
features. Microarray analysis was conducted to further map the breakpoint, but the
results did not identify the translocation breakpoint. A candidate gene for Autism
Spectrum Disorder, C2orf27A, was identified in this 80kb region on chromosome 2q.
Future studies are needed to identify the translocation breakpoint and to further study
expression levels of this candidate gene.
The studies presented in this work provide a greater understanding of genes that
cause Autism Spectrum Disorder by confirming the association with the rs1858830 C
variant of the MET gene and Autistic Disorder and by studying the in vivo functions of
two alterations in NLGN4X, a gene previously associated with Autism Spectrum
Disorder. These studies also identified a candidate gene, C2orf27A, for Autism Spectrum
Disorder located at chromosome 2q21.
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APPENDIX A
Name

Ingredients
100 mM NaCl
50 mM Tris-HCl
10 mM MgCl2
1 mM Dithiothreitol
pH 7.9 @ 25°C
50 mM potassium acetate
20 mM Tris-acetate
10 mM Magnesium Acetate
1 mM Dithiothreitol
pH 7.9 @ 25°C
In a 15 ml conical tube, dissolve 100 mg BSA
(Sigma, A-8022) in 10 ml sdH2O. Store at -20°C.
Used as an enzyme stabilizer in some restriction
enzyme digestions.
In a 1 L beaker, add 186.12 g EDTA (Mallinkrodt
through VWR, MK493104) to ~800 ml sdH2O.
Slowly add 15-20g of NaOH pellets and use the
magnetic stirrer to dissolve. The disodium salt of
EDTA will not go into solution until the pH
approaches 8.0; adjust pH to 8.0 with concentrated
HCl (Mallinkrodt through VWR, MK206204) or
4N NaOH. Add sdH2O to 1 L. Autoclave and store
at room temperature (should be refrigerated if not in
common use).

Eag I buffer (NEB buffer 3)

Mnl I and HpyCH4III buffer
(NEB buffer 4)

10X Bovine Serum Albumin (BSA)

0.5 M EDTA, pH 8.0

Weigh out 152 mg Spermidine (Sigma S-2501) and
pour it into a 15 ml screw-cap conical tube. Add sd
H2O to the 15 ml mark on the tube. Dissolve by
vortexing well. Store at -20°C. Spermidine interacts
with DNA to cause conformational changes thought
to make recognition sites more available for cutting.

10X Spermidine (40 mM)

0.5M Tris‐HCL pH6.8 1.75ml
Glcerol(Glycrin) 4.5ml
SDS (0.25g dissolved in 1ml Thris‐HCL) 2ml 0.5g
0.25% Bromophenol blue (25mg in 10ml H20)
0.5ml
B‐mercaptoethanol 1.25ml
Total of 10mls
Store in fridge and protect from light
12.11 g Tris
87.66 g NaCl
5 mL Tween-20
1 g Na-azide
Bring up the mix with 1 liter ddH20 distilled water

5X Lamelli Buffer

10X TBST
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